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Background: Ovarian cancer stem cells are characterized by self-renewal capacity, ability to differentiate into
distinct lineages, as well as higher invasiveness and resistance to many anticancer agents. Since they may be
responsible for the recurrence of ovarian cancer after initial response to chemotherapy, development of new
therapies targeting this special cellular subpopulation embedded within bulk ovarian cancers is warranted.
Methods: A high-throughput screening (HTS) campaign was performed with 825 compounds from the Mechanistic
Set chemical library [Developmental Therapeutics Program (DTP)/National Cancer Institute (NCI)] against ovarian
cancer stem-like cells (CSC) using a resazurin-based cell cytotoxicity assay. Identified sets of active compounds were
projected onto self-organizing maps to identify their putative cellular response groups.
Results: From 793 screening compounds with evaluable data, 158 were found to have significant inhibitory effects
on ovarian CSC. Computational analysis indicates that the majority of these compounds are associated with mitotic
cellular responses.
Conclusions: Our HTS has uncovered a number of candidate compounds that may, after further testing, prove
effective in targeting both ovarian CSC and their more differentiated progeny.
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Ovarian cancer is the most lethal of gynecological can-
cers [1] despite its typically high initial response rate to
chemotherapy [2]. Recent evidence supports the exist-
ence of ovarian cancer stem-like cells (CSC), character-
ized by self-renewal capacity, ability to differentiate into
distinct lineages, high invasiveness and resistance to a
number of anticancer agents [3–6]. Since CSC have been
shown to be resistant to most current chemotherapies,
the frequent recurrence of ovarian cancer is believed, at
least in part, to be attributable to the existence of
chemo-resistant sub-populations of cancer cells embed-
ded within bulk tumors [6]. For this reason, there is con-
siderable current interest in the development of new
chemotherapies that can effectively target this insidious
subpopulation of tumor cells [7].
Thus far, searches for compounds that may be
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reproduction in any medium, provided the oralternative strategies. One approach has been to evaluate
molecules known to be inhibitory against pathways
believed to be deregulated in CSC (e.g., the Hedgehog,
NOTCH, PTEN/AKT and WNT/β-catenin signaling
pathways) [8]. This approach has resulted in the identifi-
cation of several potential therapeutic agents that are
currently in clinical trials [9]. A second approach is the
high-throughput screening (HTS) of CSC-enriched cell
populations with libraries of potential inhibitory com-
pounds. This approach has been productively employed
to identify candidate compounds displaying cytotoxic/
inhibitory effects on breast cancer [10] and glioma
[11,12] CSC.
We have recently reported the isolation and
characterization of ovarian CSC from an established
ovarian cancer cell line OVCAR-3 [13]. These cells dis-
play a variety of features and molecular profiles charac-
teristic of CSC previously isolated from ovarian and
other cancer tissues [14–17]. Here we report the results
of a high-throughput screening of 825 potential drugs
(the National Cancer Institute’s “Mechanistic Set” library)ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cation of compounds that display significant potential for
future development as ovarian CSC therapeutic agents.
Methods
Cells
Spheroids were derived from OVCAR-3 cell line as pre-
viously described [13] and grown in the stem cell
medium (SCM): DMEM/F12 (1:1) supplemented with
0.4% bovine serum albumin (BSA, Sigma-Aldrich, Inc.
St. Louis, MO), 20 ng/mL epidermal growth factor (EGF,
Invitrogen Corporation, Carlsbad, CA), 10 ng/mL basic
fibroblast growth factor (bFGF, Sigma-Aldrich), 5 μg/mL
insulin (Sigma-Aldrich) and 1% antibiotic-antimycotic
solution (Mediatech-Cellgro, Manassas, VA) in 100 mm
ultra-low attachment Petri dishes (Corning Incorporated,
Corning, NY). Spheroids grown under these conditions
were dissociated weekly using 0.05% trypsin-0.02% EDTA
solution (Lonza, Walkerswille, MD) and sub-cultured
until the amount of cells was adequate for HTS.
Compounds
The NCI Mechanistic Set was provided by the Develop-
mental Therapeutic Program (NCI/NIH) as a set of 825
compounds plated in eleven 96-well plates (plate num-
bers: 4520–4530; suffix: 69). Basic information on these
compounds can be retrieved from the DTP website [20]
using plate number as the search parameter. These com-
pounds were selected from 37,836 compounds in the
NCI repository to represent a broad range of growth in-
hibition patterns in the NCI 60 cell line screen [18,19]
and consequently, they likely represent a diversity of the
modes of action of these compounds. Compounds were
supplied by DTP as 1 mM solutions in DMSO.
HTS and data analysis
Spheroids were dissociated to single cells using trypsin;
trypsin was neutralized using Soybean Trypsin Inhibitor
(Life Technologies, Grand Island, NY; Catalogue #
17075029), and cells were re-suspended in SCM to a
density of 50,000 cells/mL. Cells were plated into flat
bottom ultra-low attachment 96 well plates (Corning,
Product #3474) in a volume of 198 μL per well (200 μL
of SCM for blank wells) and incubated for 24 h at 37°C
and humidified atmosphere with 5% CO2. Drug dilutions
were prepared as follows: the eleven supplied NCI
Mechanistic Set plates were copied (4 μL of DMSO solu-
tion per well) into sterile, round bottom polypropylene
96-well plates (Corning, Product #3359) and each drug
was diluted with 22 μL media (working concentrations
153.8 μM). 3 μL of diluted library were added to 198 μL
of cells (4 replicated wells for each drug), which resulted
in final drug concentration of 2.29 μM. The plates were
incubated for 96 h at 37°C and humidified atmospherewith 5% CO2. Thereafter, 20 μL of TOX8 reagent
(Sigma-Aldrich) were added to each well and after 4-h
incubation fluorescence intensities were measured for
each well at 560 nm (excitation) and 590 nm (emission).
The resazurin (Alamar blue)-based TOX8 reagent has
been previously established as a reliable method for de-
termining cell viability/cytotoxicity of tumor spheroid
cell cultures [21,22].
Fluorescence intensities for replicated wells were ana-
lyzed using Grubb’s test for detecting outliers at critical
Z = 1.48 and outliers were removed from the dataset
(test was applied only once for each replicated set of
values). Percent growth of treated cells relative to
untreated control cells was calculated from fluores-
cence intensities using the formula: %growth ¼ 100
average for treated cells  average for blank wellsð Þ½ =
average for untreated cellsð Þ½ average for blank wellsð Þ
Other parameters recommended by Inglese et al. [23],
HTS plate design, assay performance evaluation and sys-
tematic error detection are presented in Additional file 1.
Of the 793 compounds that passed our assay perform-
ance standard, 99 displayed a single outlier among 4
replicated fluorescence intensity values and these outliers
were removed before % growth values were calculated.
Statistical significance of differences between fluores-
cence intensities of drug-treated and untreated control
wells was evaluated using Welch’s t-test followed by
Holm’s step-down method for multiplicity adjustment
[24]. Two-sided p-values were determined by Welch’s
t-test from raw fluorescence intensities corresponding
to replicated treated and untreated control wells. These
p-values represent probabilities that the difference be-
tween mean signal intensities for treated and control
wells were obtained by chance. Holm’s procedure was
applied to 793 p-values (compounds that passed assay
performance test) to counteract the problem of multiple
comparisons and to ascertain that the probability of
falsely identifying one or more compounds as signifi-
cantly affecting growth of ovarian cancer stem-like cells
is not more than 10%. Thus, compounds selected by
controlling for family-wise error rate (FWER) of 0.10
were classified as compounds with statistically signifi-
cant effect on growth of ovarian cancer stem-like cells.
Drugs with % growth 80-110% were considered as com-
pounds with no effect on growth of ovarian cancer
stem-like cells.
Results of HTS were interpreted (i) in the context of
the activity of FDA-approved drugs present in the li-
brary; (ii) in comparison with the potencies of screened
compounds against OVCAR-3 cell line (parental cells
from which CSC were isolated), and (iii) via mapping to
self-organizing maps (SOMs).
A list of 97 FDA-approved oncology drugs was built
from the data on the Approved Oncology Drug Set
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Additional file 2.
Potencies of library compounds against OVCAR-3 cell
line (Dec 2010 release) were retrieved from the DTP
website [26]. If multiple GI50 values were available for
the same compound, the average was taken without in-
clusion of default values (Note: NCI does not provide
descriptive statistics (SD or SEM) for the determined
GI50 values for tested cells).
All 793 library compounds that passed our assay per-
formance criteria and selected subsets of compounds ac-
tive against CSC were mapped onto SOMs using the
web-based tool 3D MIND developed by the Covell
group at the National Cancer Institute [27]. The SOM
method represents a type of artificial neural network
trained using unsupervised learning to cluster high di-
mensional data and project them into a low dimensional
space. SOMs used in this work was generated from GI50
values for ~30,000 compounds across 60 cell lines and
consists of 1,350 hexagonal clusters with 9 major cellular
response categories: mitosis (M), membrane function
(N), nucleic acid metabolism (S), metabolic stress and
cell survival (Q), kinases/phosphatases and oxidative
stress (P) and 4 unexplored regions (RFJV) [28]. The sig-
nificance of differences in the distribution of CSC active
subsets and all library compounds to these areas was
evaluated using Fisher’s exact test with Yate’s continuity
correction and the difference was considered significant
for two-sided p-value < 0.01.
Determination of GI50
GI50 values (concentrations of tested agents that inhib-
ited growth of CSC cell cultures after 96-h incubation
to 50% of the untreated control) were determined
for 5 compounds (NSC72961, NSC302979, NSC82116,
NSC673622 and NSC243928) randomly selected from
those resulting in ≤ 50% cellular growth relative to un-
treated controls. GI50 values were determined from
concentration-response data generated by the same
assay and cell system as used in our HTS. For each
compound, 5 concentrations were used (15.6 nM, 62.5
nM, 250 nM, 1000 nM and 4,000 nM). Percent growth
(control based normalization) was calculated as
described in (Additional file 1: Table S1) and GI50 values
were determined by non-linear regression of log-
transformed data using a normalized response-variable
slope model (GraphPad Prism 5.01; GraphPad Software,
Inc.) and expressed as mean ± SEM.
Results and discussion
HTS identified over 100 compounds that significantly
inhibit ovarian CSC growth
NCI’s Developmental Therapeutics Program (DTP) main-
tains a repository of synthetic and naturally occurringpotential anticancer drugs. A sub-set of these com-
pounds, termed the “Mechanistic Set”, represents the
range of distinct growth inhibition patterns observed
when the repository compounds were tested against the
NCI-60 panel of cancer cell lines [18,19].
The CSC culture used in this study was derived
from OVCAR-3 cells and is composed of tumor
spheroids enriched with slowly proliferating self
renewing stem-like cells that have been previously
demonstrated to resist apoptosis after detachment from
the surface (anoikis), a property known to be prerequisite
for invasion and metastasis [13]. In addition, these cells
have been shown to display significantly higher invasive-
ness, migration potential, and resistance to standard
anticancer agents relative to the parental OVCAR-3 cells,
as well as an ability to differentiate from a CD44-positive/
mesenchymal-like phenotype to CD44-negative/epithelial
like phenotype [13].
CSC were seeded in 96-well plates and allowed to pro-
liferate for 24 h prior to exposure to the 825 compounds
comprising the NCI Mechanistic Set of experimental
compounds (chemical library). After 96 h of exposure, %
growth of treated cells relative to untreated controls was
determined. To reduce the possibility of spurious results,
we conducted an assay performance test and subse-
quently excluded 32 compounds from our survey that
were associated with unreliable results (Additional file 3).
Of the remaining 793 compounds (Additional file 4),
329 (41.5%) did not display an appreciable effect on
ovarian CSC growth (80-110% growth), while 161 com-
pounds (20.3%) displayed a statistically significant effect
at FWER=0.10 with 158 compounds displaying an inhi-
biting effect (3.3-74.1% growth) and 3 compounds dis-
playing a stimulatory effect (135.6-158.7% growth).
In order to focus on the most inhibitory compounds,
we operationally defined CSC inhibitory compounds as
those displaying a ≤ 50 % cell growth relative to un-
treated controls. Based on these criteria, 136 of the 793
compounds (17.2%) were classified as inhibitory (range
of inhibitory growth: 3.3-50.4%) (Table 1). These 136
inhibitory compounds are listed in Table 1 by a NCI
compound number (NSC). A full list the various names
associated with each NCI compound number is avail-
able as an ASCII file at the National Cancer Institute’s
Developmental Therapeutics Program website [29].
We randomly selected 5 of the 136 inhibitory com-
pounds for confirmatory testing. In each case, the deter-
mined GI50 values were indicative of a significant
inhibitory effect: NSC72961: 104.2±13.54 nM; NSC302979:
814.0±84.44 nM; NSC82116: < 1 nM; NSC673622: 865.2
nM (SEM not determined); NSC243928: 831.6±134.72 nM
(Figure 1). The cellular phenotype of CSC after treat-
ment with inhibitory compounds is consistent with cell
death/apoptosis (Figure 2).
Table 1 List of 136 CSC-inhibitory compounds identified
by HTS (%growth ≤ 50%, p-adj. ≤ 0.1) compared to GI50
of OVCAR-3 cells




618332 3.3 4.0 3.73E-07 2.78E-04 5.08
219734 4.2 2.0 9.47E-07 6.88E-04 6.43
128305 4.9 3.4 8.02E-06 5.59E-03 4.34
168597 5.1 5.5 2.42E-06 1.73E-03 7.69
328426 5.3 3.2 4.64E-07 3.44E-04 7.62
143648 5.6 2.3 1.64E-07 1.23E-04 7.43
165563 6.1 4.4 3.58E-07 2.67E-04 8.05
145366 7.1 2.1 5.21E-08 4.00E-05 5.75
636132 7.3 3.2 9.47E-07 6.89E-04 4.00
323241 7.7 2.4 1.59E-07 1.20E-04 7.54
622732 8.0 4.9 4.93E-06 3.46E-03 4.90
208913 8.0 3.5 8.17E-07 5.96E-04 3.80
306864 8.0 3.1 3.86E-07 2.88E-04 5.76
4320 8.0 3.3 6.94E-08 5.31E-05 9.56
3053 8.4 3.9 1.38E-08 1.07E-05 8.54
265450 8.5 3.2 8.14E-08 6.21E-05 7.20
354844 8.6 6.0 4.34E-07 3.22E-04 7.26
164914 8.8 3.7 2.95E-09 2.32E-06 6.75
63701 8.9 3.4 1.00E-09 7.88E-07 7.46
697726 9.0 3.5 5.32E-09 4.16E-06 7.56
637578 9.1 2.3 1.04E-07 7.87E-05 8.36
614928 9.3 2.0 7.60E-07 5.56E-04 4.51
667467 9.8 3.9 3.53E-10 2.79E-07 4.00
65937 10.2 2.1 1.08E-07 8.16E-05 -
65423 10.4 3.1 2.61E-10 2.06E-07 5.78
690634 10.8 2.9 7.52E-07 5.51E-04 7.59
24559 10.8 3.6 9.91E-11 7.86E-08 7.35
18268 10.9 3.4 2.24E-08 1.73E-05 8.41
243023 11.0 3.4 4.48E-06 3.15E-03 8.07
635448 11.1 5.9 1.19E-08 9.27E-06 7.69
7525 11.3 2.4 4.99E-06 3.49E-03 7.60
616232 11.6 4.0 3.97E-10 3.13E-07 4.00
269754 11.9 8.4 1.62E-04 1.03E-01 8.10
680506 12.4 5.0 4.85E-07 3.58E-04 -
58514 12.5 3.1 1.34E-08 1.04E-05 9.52
353527 12.8 4.1 7.25E-07 5.32E-04 7.77
106408 12.8 2.4 1.29E-06 9.30E-04 7.34
620358 13.0 5.5 1.37E-05 9.27E-03 5.72
65104 13.2 4.3 9.57E-07 6.95E-04 8.76
325319 13.2 2.7 7.94E-07 5.80E-04 8.23
328166 13.4 5.4 4.72E-07 3.49E-04 7.35
658144 13.4 2.6 1.51E-08 1.17E-05 6.68
Table 1 List of 136 CSC-inhibitory compounds identified
by HTS (%growth ≤ 50%, p-adj. ≤ 0.1) compared to GI50
of OVCAR-3 cells (Continued)
260610 13.9 5.5 2.48E-06 1.77E-03 6.79
631529 14.5 3.2 4.08E-07 3.04E-04 5.82
85236 14.5 2.5 8.67E-08 6.61E-05 5.82
376265 14.7 7.5 1.41E-05 9.53E-03 8.50
349644 14.9 4.6 2.95E-05 1.95E-02 7.72
89671 15.0 2.5 6.73E-07 4.95E-04 7.55
105808 15.3 3.8 1.15E-05 7.87E-03 5.96
635121 16.0 5.3 9.44E-06 6.53E-03 5.52
93419 17.1 7.4 2.92E-05 1.93E-02 6.13
268251 17.4 6.2 2.99E-06 2.12E-03 8.96
202000 17.7 5.0 3.03E-09 2.38E-06 4.05
659999 18.0 6.4 1.30E-08 1.01E-05 5.99
172924 18.5 3.1 7.81E-08 5.97E-05 6.67
673622 18.5 9.1 1.83E-05 1.23E-02 6.59
146604 19.2 4.6 2.41E-09 1.90E-06 6.65
349156 19.5 2.6 1.73E-06 1.24E-03 6.92
526417 19.7 3.8 5.38E-08 4.13E-05 9.28
400978 20.3 2.4 7.26E-09 5.67E-06 7.97
24817 20.4 5.8 2.23E-08 1.72E-05 7.67
319726 20.6 4.0 5.30E-09 4.15E-06 8.00
614826 20.8 5.2 1.41E-05 9.52E-03 6.66
679524 20.9 3.5 1.94E-10 1.54E-07 7.50
629301 20.9 5.5 2.23E-05 1.49E-02 4.80
129414 21.1 7.4 5.48E-05 3.58E-02 7.41
337766 21.4 5.8 1.20E-08 9.34E-06 6.73
7532 21.7 8.3 3.12E-06 2.21E-03 8.00
172946 21.7 5.6 1.25E-05 8.50E-03 7.46
328587 22.1 4.6 2.91E-09 2.29E-06 5.77
34391 22.2 4.2 4.20E-07 3.12E-04 5.60
153858 22.5 4.8 9.62E-07 6.97E-04 9.48
625483 22.8 9.7 2.53E-05 1.68E-02 4.66
82116 23.0 5.7 1.02E-07 7.75E-05 -
72961 23.1 4.4 1.27E-07 9.59E-05 5.60
65380 23.6 6.9 9.38E-05 6.03E-02 7.20
85700 23.7 4.7 1.18E-08 9.20E-06 5.98
336628 23.7 5.9 2.62E-07 1.97E-04 4.77
345647 23.8 48.5 1.03E-05 7.09E-03 6.59
102811 23.9 5.3 1.99E-08 1.54E-05 6.96
669356 24.5 8.1 2.09E-06 1.49E-03 8.00
7521 24.5 6.9 9.49E-05 6.08E-02 7.52
352876 24.7 6.7 4.35E-05 2.86E-02 6.27
148958 24.9 6.9 1.03E-07 7.81E-05 3.09
613009 25.0 5.7 3.89E-06 2.75E-03 7.41
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Table 1 List of 136 CSC-inhibitory compounds identified
by HTS (%growth ≤ 50%, p-adj. ≤ 0.1) compared to GI50
of OVCAR-3 cells (Continued)
10447 25.5 6.6 3.49E-07 2.61E-04 4.65
301460 25.6 5.0 2.20E-06 1.57E-03 8.00
605756 25.8 6.4 6.31E-07 4.65E-04 5.68
407806 26.5 3.1 1.95E-06 1.40E-03 7.44
67574 27.0 6.0 1.21E-06 8.74E-04 7.68
700582 27.2 5.8 1.02E-07 7.74E-05 6.57
304421 27.9 4.2 4.98E-06 3.49E-03 6.47
521777 28.1 6.1 3.29E-08 2.53E-05 8.00
330500 29.0 4.8 6.10E-07 4.50E-04 6.05
255109 29.6 4.9 1.15E-05 7.84E-03 7.02
302979 30.4 10.8 5.65E-05 3.68E-02 5.43
33410 30.8 5.6 6.80E-08 5.21E-05 7.98
693632 30.8 7.4 2.11E-07 1.58E-04 6.44
24818 31.0 5.3 9.92E-06 6.85E-03 8.12
24819 31.1 4.7 1.14E-06 8.25E-04 8.47
52141 31.3 6.0 1.14E-06 8.24E-04 7.14
96932 31.4 6.9 6.94E-07 5.10E-04 6.77
349155 31.7 7.1 1.99E-05 1.33E-02 6.45
97911 32.4 7.6 6.23E-05 4.05E-02 5.70
243928 32.5 9.0 8.80E-06 6.11E-03 5.69
83265 34.8 6.7 4.05E-06 2.86E-03 5.70
637993 34.8 9.9 8.30E-05 5.36E-02 5.50
145669 34.9 6.6 3.26E-07 2.44E-04 7.75
157930 34.9 6.5 5.26E-06 3.68E-03 6.16
132791 35.2 15.3 1.52E-04 9.67E-02 6.96
331757 35.6 15.4 1.55E-04 9.84E-02 5.11
269142 36.0 10.3 9.02E-06 6.25E-03 6.68
1906 36.2 3.5 4.46E-08 3.43E-05 4.15
14229 37.6 6.1 9.93E-08 7.56E-05 5.55
1620 37.7 8.4 4.88E-06 3.43E-03 4.00
622627 38.4 11.4 1.82E-05 1.22E-02 5.28
215989 38.6 7.1 2.91E-06 2.07E-03 -
13973 40.2 5.5 1.38E-06 9.94E-04 6.28
332598 40.6 7.4 2.18E-05 1.45E-02 10.38
126727 41.3 11.0 6.20E-05 4.04E-02 -
248436 41.4 9.5 1.35E-05 9.15E-03 4.08
705330 41.6 10.5 1.35E-05 9.17E-03 5.70
166454 41.9 7.2 8.76E-07 6.39E-04 5.41
84074 42.9 7.3 1.84E-05 1.23E-02 5.46
632841 43.2 6.1 1.47E-06 1.06E-03 5.83
116693 43.6 5.1 1.86E-07 1.40E-04 5.50
375575 44.8 5.1 1.04E-05 7.14E-03 5.71
98904 45.5 11.5 1.23E-04 7.85E-02 6.05
Table 1 List of 136 CSC-inhibitory compounds identified
by HTS (%growth ≤ 50%, p-adj. ≤ 0.1) compared to GI50
of OVCAR-3 cells (Continued)
629971 46.5 10.7 1.01E-05 6.96E-03 6.54
403883 48.3 7.0 2.37E-05 1.57E-02 4.00
267033 48.5 10.9 4.31E-05 2.84E-02 6.35
36437 48.5 5.5 8.51E-06 5.91E-03 5.23
49842 49.1 10.6 2.34E-05 1.56E-02 9.71
654259 49.8 9.0 2.57E-06 1.83E-03 7.23
182986 50.1 9.1 1.52E-05 1.02E-02 5.27
93739 50.4 6.5 1.54E-05 1.04E-02 5.40
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performance test are 19 drugs previously approved by
the FDA for cancer treatment (Table 2). Five of these
drugs are among the 136 compounds designated as
CSC-inhibitory, but none are commonly used in the
treatment of epithelial ovarian cancer. On the other
hand, triethylenemelamine (altretamine, NSC9706), which
is used for palliative treatment of persistent or recurrent
ovarian cancer [30], induced non-significant stimulation
of CSC growth in our screening (Table 2).
The two most CSC-inhibitory of the FDA-approved
drugs, dactinomycin (NSC 3035; 8.4% cell growth) [31]
and plicamycin (mithramycin A, NSC 24559; 10.8% cell
growth) [32] have both been previously reported to in-
duce programmed cell death or apoptosis by inhibiting
RNA transcription. Dactinomycin is used in the treat-
ment of several cancers including gestational tropho-
blastic neoplasia [33] and Wilms’ tumor [34]. Plicamycin
has been used in the treatment of testicular cancer [35]
and hypercalcemia associated with advanced malignancy
[36]. The anti-microtubule drug vincristine (NSC24559)
is used in the treatment of acute leukemias, Hodgkin
lymphoma, and aggressive non-Hodgkin lymphoma,
but is also included in combinations for treatment of
small-cell lung cancer, breast cancers and some pediatric
neoplasms [37]. Vinblastine (NSC49842) is used in the
treatment of Hodgkin’s lymphoma [37], and in combin-
ation with cisplatin and bleomycin in the treatment of
testicular and ovarian germ cell cancers [38]. Mepacrine
(quinacrine, NSC14229), an inhibitor of NFκB [39] and
topoisomerase activity [40], is primarily used as an anti-
malarial drug [41]. In oncology, it is most commonly
used for the treatment of pleural effusions in advanced
malignant diseases [42].Most ovarian CSC growth-inhibiting compounds also
inhibit the growth of more differentiated ovarian cancer
cells
It has been established previously that normal stem
cells are more resistant to the induction of apoptosis
Figure 1 Concentration-response curves for 5 library compounds identified as inhibitors of ovarian cancer stem-like cells. Curves are
fitted by non-linear regression of log-transformed data using a normalized response-variable slope model. Error bars: SEM.
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tiated progeny and similarly, CSC have been shown
to display increased resistance to these same agents
relative to the more differentiated cells that comprise
the bulk of the tumor [43–45]. Indeed, it has been
proposed that this dichotomy may contribute to the
recurrence of cancer growth after the initial response
of tumors to chemotherapeutic treatments [46]. Con-
sistent with this view, we previously reported that
several ovarian cancer drugs (e.g., NSC119875-cisplatin,
NSC724770-docetaxel, NSC609699-topotecan) that are
effective against ovarian cancer OVCAR-3 cells, are sig-
nificantly less effective at inhibiting growth of ovarian
CSC [13]. To assess if the apparent dichotomy in drug
effectiveness between ovarian CSC and their moredifferentiated progeny is characteristic of the 136 ovarian
CSC inhibitory compounds identified in our study, we
sought to compare the results of our HTS with NCI’s
previous testing of compounds against the OVCAR-3
cell line. In the NCI program, GI50 values (concentra-
tions required to inhibit growth by 50%) on OVCAR-3
cells were determined for nearly all of the compounds
used in our HTS. The OVCAR-3 GI50 values (expressed
as -log10 GI50) for 136 of the CSC-inhibitory compounds
are presented in Table 1. The data output from our HTS
is relative % growth rather than GI50 values. However,
since the concentration of compounds used in our HTS was
2.29 μM (see Methods), the GI50 for compounds resulting
in ≤ 50% growth of CSC is predicted to be ≤ 2.29 μM or
≥ 5.64 on the -log10 scale (−log10 2.29×10
-6 = 5.64). By
Figure 2 Phenotypic effect of compound NSC72961 (8-azaadenosine) at 4 μM (96 h) on ovarian cancer stem-like cell culture. Test
treatment (A); solvent control (B). Scale bar = 50 μm.
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http://www.ovarianresearch.com/content/5/1/30comparing this value with the -log10 GI50 values previously
determined for OVCAR-3 cells in the NCI study, we
found that 73% (99/136) of the compounds that we
designated as CSC inhibitory compounds are also inhibi-
tory for OVCAR-3 cells (i.e., -log10 GI50 ≥ 5.64). This sug-
gests that there may be a number of inhibitory
compounds with the potential to target both ovarian CSC
and their more differentiated progeny. Of the remaining
37 (136–99) CSC-inhibitory compounds, 5 were notTable 2 Results of HTS of CSC with 19 FDA-approved oncolog



















45388 Dacarbazine 164.3previously tested on OVCAR-3. Thus, based on our cri-
teria, we classified 32 compounds to be preferentially in-
hibitory for CSC (Table 3).
Among the 99 compounds found to be co-inhibitory for
CSC and OVAR-3 cells, four have previously been FDA
approved for cancer treatment (NSC3053-dactinomycin;
NSC24559-plicamycin; NSC49842-vinblastine; NSC67574-
vincristine) (Table 2). Only one of the previously approved
cancer drugs, the NFκB-inhibitor Mepacrine (NSC14229),y drugs
D (%) p-value p-adj GI50 OVCAR3
(−log10)
3.9 1.38E-08 1.07E-05 8.54
3.6 9.91E-11 7.86E-08 7.35
6.0 1.21E-06 8.74E-04 7.68
6.1 9.93E-08 7.56E-05 5.55
10.6 2.34E-05 1.56E-02 9.71
10.2 1.10E-05 7.54E-03 5.28
11.0 1.04E-02 1 5.00
17.0 7.13E-02 1 4.59
8.4 2.83E-01 1 5.94
30.8 8.38E-01 1 6.69
20.9 7.93E-01 1 8.17
12.0 9.18E-01 1 3.13
28.9 8.10E-01 1 3.14
14.8 2.38E-01 1 2.92
14.3 4.45E-02 1 5.23
15.9 3.65E-02 1 3.60
47.6 2.68E-01 1 4.73
82.5 5.26E-01 1 4.74
14.2 4.46E-04 2.68E-01 4.25
Table 3 Compounds preferentially inhibitory for CSC
NSC Name % growth SD p-adj
618332 2,3-Dibromonaphthoquinone 3.3 4.0 2.78E-04
128305 5,7-Dihydroxy-3',4'-dimethoxyflavone 4.9 3.4 5.59E-03
636132 3-Cyano-N,3-bis(2-methylphenyl)-2-oxopropanamide 7.3 3.2 6.89E-04
622732 N-(4-chlorophenyl)-1-methyl-1H-pyrazolo[3,4-b]quinolin-5-amine 8.0 4.9 3.46E-03
208913 Ethyl 2-(((1-adamantyl(methyl)amino) carbonyl)amino)propanoate 8.0 3.5 5.96E-04
614928 3,3,4,4-Tetramethyltetrahydro-2,5-furandiol 9.3 2.0 5.56E-04
667467 2-Phenyl-1,4-thiazino[3,2-c]quinoline-3-thione 9.8 3.9 2.79E-07
616232 Dibromodulcitol 11.6 4.0 3.13E-07
635121 N'-(1-(4H-1,4-benzothiazin-2-yl)ethylidene)-2-hydroxybenzohydrazide 16.0 5.3 6.53E-03
202000 (4Z)-4-[(3,4-dichlorophenyl) methylidene]-2-(furan-2-yl)-1,3-oxazol-5-one 17.7 5.0 2.38E-06
629301 3,6-Dihydro-3,6-ethanocyclohepta[cd][1]benzofuran-10,10,11,11-tetracarbonitrile 20.9 5.5 1.49E-02
34391 Cryptocyanine iodide 22.2 4.2 3.12E-04
625483 1-(2-Chloro-6-fluorophenyl)-1H,3H-Thiazolo(3,4-a)benzimidazole 22.8 9.7 1.68E-02
72961 8-Azaadenosine 23.1 4.4 9.59E-05
336628 Merbarone 23.7 5.9 1.97E-04
148958 Ftorafur 24.9 6.9 7.81E-05
10447 Purpurin 25.5 6.6 2.61E-04









1906 Piperidinium piperidinedithiocarbamate 36.2 3.5 3.43E-05
14229 Mepacrine 37.6 6.1 7.56E-05
1620 4-[[(2-furanyl)methyl]amino]-1H-pyrazolo[3,4-D]pyrimidine 37.7 8.4 3.43E-03
622627 2-(chloromethyl)-1,3-dinitro-5-(trifluoromethyl)benzene 38.4 11.4 1.22E-02
248436 Platinum, dibromo(6-thioguanosine-N7,S6)-, (SP-4-3)- 41.4 9.5 9.15E-03
166454 Decamine 41.9 7.2 6.39E-04
84074 Phosphonium, (3-bromopropyl)triphenyl- bromide 42.9 7.3 1.23E-02
116693 2,3-bis(benzoyloxy)succinic acid compound with
1,4-dimethyl-2-((4-methylphenyl)(phenyl)-l 4-sulfanyl)benzene (1:1)
43.6 5.1 1.40E-04
403883 Cedran-8-ol 48.3 7.0 1.57E-02
36437 Crassin acetate 48.5 5.5 5.91E-03
182986 Diaziquone 50.1 9.1 1.02E-02
93739 Fuchsine 50.4 6.5 1.04E-02
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entially inhibitory for ovarian CSC (37.6% growth).
Computational model classifies CSC inhibitory
compounds into predicted cellular response groups
Neither the mode of action nor the molecular targets
of the 32 compounds classified by us as preferen-
tially inhibitory for CSC have, as yet, been definitivelydetermined. However, there are a variety of computa-
tional tools that can be informative in predicting the
putative cellular responses to these compounds and in
suggesting lines of future investigation. One such tool,
developed by the Covell group at NCI [27,28,47], uti-
lizes data from the treatment of 60 representative
human cancer cell lines (the NCI-60 panel) [48] with
nearly 30,000 compounds including those investigated
Figure 3 Mapping of compounds used in the HTS onto SOMs. (a) all 793 evaluable compounds (b) 136 CSC inhibitory compounds; (c) 99
CSC and OVCAR-3 co-inhibitory compounds; (d) 32 CSC-specific inhibitory compounds. [mitosis (M), membrane function (N), nucleic acid
metabolism (S), metabolic stress and cell survival (Q), kinases/phosphatases and oxidative stress (P) and 4 unexplored regions (RFJV)].
Table 4 Number of compounds mapping into individual cellular response categories of SOM
F J M N P Q R S V
(a) 29 (4.2%) 44 (6.4%) 129 (18.7%) 102 (14.8%) 92 (13.3%) 83 (12.0%) 25 (3.6%) 140 (20.3%) 46 (6.7%)
(b) 5 (2.6%) 7 (3.6%) 70 (36.1%) 16 (8.2%) 25 (12.9%) 13 (6.7%) 5 (2.6%) 42 (21.6%) 11 (5.7%)
(c) 3 (1.9%) 5 (3.1%) 62 (38.5%) 16 (9.9%) 19 (11.8%) 9 (5.6%) 3 (1.9%) 35 (21.7%) 9 (5.6%)
(d) 2 (7.4%) 1 (3.7%) 6 (22.2%) 0 (0%) 5 (18.5%) 4 (14.8%) 1 (3.7%) 7 (25.9%) 1 (3.7%)
p-ab 0.3988 0.1653 <0.0001 0.0169 1.0000 0.0365 0.6537 0.6882 0.7412
p-ac 0.2469 0.1326 <0.0001 0.1283 0.6970 0.0163 0.3325 0.6663 0.7235
p-ad Numbers too small for statistical evaluation
(a) all 793 evaluable compounds (b) 136 CSC inhibitory compounds; (c) 99 CSC and OVCAR-3 co-inhibitory compounds; (d) 32 CSC-specific inhibitory compounds.
P-values: Fisher’s exact test for the significance of differences between proportions of compounds in a given cellular response category in 793 compound set (A)
and compound subset B (p-AB), C (p-AC), or D (p-AD). [mitosis (M), membrane function (N), nucleic acid metabolism (S), metabolic stress and cell survival (Q),
kinases/phosphatases and oxidative stress (P) and 4 unexplored regions (RFJV)].
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http://www.ovarianresearch.com/content/5/1/30in our HTS. These data were used to generate a self-
organizing map (SOM) that visualizes the position of
~30,000 screened compounds within 9 major cellular
response categories: mitosis (M), membrane function
(N), nucleic acid metabolism (S), metabolic stress and
cell survival (Q), kinases/phosphatases and oxidative
stress (P) and 4 unexplored regions (RFJV).
Using this SOM, we were able to visually compare the
predicted cellular responses of all of our screened com-
pounds (that passed assay performance criteria) relative
to those identified as having an inhibitory effect on CSC.
Shown in Figure 3 is a SOM upon which we have
mapped (a) all 793 compounds used in our HTS; (b) the
136 compounds identified as inhibitors of CSC (includ-
ing compounds that also inhibit OVCAR-3 cells); (c) the
99 compounds identified as co-inhibitory of CSC and
OVCAR-3 cells; and (d) the 32 compounds that exert a
CSC-specific inhibitory effect.
The results indicate that compared to all 793 evaluable
compounds, the 136 identified as inhibitory for CSC are
highly significantly enriched for compounds associated
with M (mitotic) cellular responses (M: 36.1% vs 18.7%;
p<0.0001; Figure 3b and Table 4). This region of SOM
contains many compounds known to interfere with
microtubule and/or actin filaments, such as taxanes,
derivatives of colchicine, vinca alkaloids, rhizoxin and
nocodazole [47]. This region also contains compounds
associated with inhibition of the DNA polymerase path-
way and is associated with the Gene Ontology (GO)
terms: Mitotic checkpoint, Cytokinesis, DNA topological
change, Cell cycle (Biological Processes); Nucleus, Kin-
etochore (Cellular Components), and DNA topoisomer-
ase activity (Molecular Function) [28].
The 99 compounds that were co-inhibitory for
OVCAR-3 and CSC also displayed a significant enrich-
ment for M cellular responses (M: 38.5% vs 18.7%;
p<0.0001; Figure 3c and Table 4). When the 32 com-
pounds classified as preferentially inhibitory for CSC
were mapped, the enrichment for M (mitotic) cellular
responses was no longer apparent (Figure 3d). Although
this may be attributable to the fact that CSC are less
mitotically active than cancer epithelial cells [43], the
relatively small number of compounds (32) in this cat-
egory precludes definitive conclusions.
Conclusion
We tested the inhibitory effect of 825 compounds
(NCI Mechanistic Set) on the growth of ovarian CSC
derived from a previously established epithelial ovarian
cancer cell line (OVCAR-3) [13]. 158 of these com-
pounds were found to have a significant inhibitory effect
on ovarian CSC growth. The most inhibitory of these
compounds (≤ 50% growth relative to controls) were
designated as CSC inhibitory. Among these 136 CSCinhibitory compounds are 5 FDA-approved cancer
drugs, but none of these are commonly used in the
treatment of epithelial ovarian cancer. A comparison of
the ovarian CSC inhibitory compounds identified in this
study with compounds previously shown to be inhibi-
tory for OVCAR-3 ovarian cancer cells revealed an un-
expected 73% overlap. Computational analysis indicates
that the majority of these compounds are associated
with mitotic cellular responses.
While epithelial ovarian cancer is frequently respon-
sive to current chemotherapeutic treatments, disease re-
currence remains a persistent problem that has been, at
least partially, attributed to the fact that ovarian CSC are
resistant to standard therapies [6,13]. Our HTS has
uncovered a number of candidate compounds that may,
after further testing, prove effective in targeting both
ovarian CSC and their more differentiated progeny.
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